Sutro BiopharmaSTRO
STRO
About: Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers.
Employees: 306
0
Funds holding %
of 6,809 funds
0
Analysts bullish %
of 4 analysts
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
121% more call options, than puts
Call options by funds: $268K | Put options by funds: $121K
85% more first-time investments, than exits
New positions opened: 24 | Existing positions closed: 13
61% more repeat investments, than reductions
Existing positions increased: 50 | Existing positions reduced: 31
16% more capital invested
Capital invested by funds: $186M [Q2] → $216M (+$30.4M) [Q3]
9% more funds holding
Funds holding: 119 [Q2] → 130 (+11) [Q3]
1.31% less ownership
Funds ownership: 77.58% [Q2] → 76.28% (-1.31%) [Q3]
Research analyst outlook
4 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$4
113%
upside
Avg. target
$11
485%
upside
High target
$17
804%
upside
4 analyst ratings
3 positive
75%
1 neutral
25%
0 negative
0%
Wells Fargo | 113%upside $4 | Equal-Weight Maintained | 11 Dec 2024 |
JMP Securities Reni Benjamin 17% 1-year accuracy 6 / 36 met price target | 804%upside $17 | Market Outperform Reiterated | 11 Dec 2024 |
HC Wainwright & Co. Andrew Fein 32% 1-year accuracy 105 / 327 met price target | 538%upside $12 | Buy Reiterated | 18 Nov 2024 |
Piper Sandler Edward Tenthoff 23% 1-year accuracy 10 / 43 met price target | 485%upside $11 | Overweight Reiterated | 11 Oct 2024 |
Financial journalist opinion
Positive
Zacks Investment Research
1 month ago
Sutro Biopharma (STRO) Upgraded to Buy: Here's What You Should Know
Sutro Biopharma (STRO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Negative
Zacks Investment Research
1 month ago
Sutro Biopharma, Inc. (STRO) Reports Q3 Loss, Misses Revenue Estimates
Sutro Biopharma, Inc. (STRO) came out with a quarterly loss of $0.59 per share versus the Zacks Consensus Estimate of a loss of $0.74. This compares to loss of $0.81 per share a year ago.
Neutral
GlobeNewsWire
1 month ago
Sutro Biopharma Reports Third Quarter 2024 Financial Results and Business Highlights
- Expects to deliver three Investigational New Drug (IND) applications in next three years based on next-generation ADC technology -
Neutral
GlobeNewsWire
1 month ago
Sutro Biopharma Demonstrates Meaningful ADC Innovation with Five Presentations at the 15th Annual World ADC Conference
SOUTH SAN FRANCISCO, Calif., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that the company will have five presentations at the 15th Annual World ADC Conference, taking place in San Diego, November 4-6, 2024.
Neutral
GlobeNewsWire
1 month ago
Sutro Biopharma Announces Initiation of the Registration-enabling REFRαME-P1 Trial with Luvelta for Pediatric Patients with CBF/GLIS AML
SOUTH SAN FRANCISCO, Calif., Nov. 01, 2024 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that REFRαME-P1, the registration-directed study of luveltamab tazevibulin (luvelta) for pediatric patients with CBFA2T3::GLIS2 (CBF/GLIS; RAM phenotype) acute myeloid leukemia (AML), has been initiated and is open for enrollment.
Neutral
GlobeNewsWire
2 months ago
Sutro Biopharma Highlights Next-Generation ADC Innovation and Near-term Pipeline at Research Forum
Proprietary cell-free platform enables the design of next-generation ADCs intended to broaden addressable patient populations
Positive
Seeking Alpha
2 months ago
Sutro Biopharma's Competitive ADCs Position It For Future Growth In Oncology
STRO specializes in ADCs for oncology, leveraging XpressCF and XpressCF+ platforms for precise antibody-drug conjugates without living cells. STRO-002, a promising ADC for ovarian cancer, has shown favorable safety and efficacy in trials, with potential FDA approval by 2026-2027. Collaborations with Merck, Vaxcyte, and Astellas Pharma could generate up to $3 billion in milestone payments.
Neutral
GlobeNewsWire
3 months ago
Sutro Biopharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif., Sept. 20, 2024 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody-drug conjugates (ADCs), today announced that on September 16, 2024, the Compensation Committee of Sutro's Board of Directors granted 60,000 restricted stock units (RSUs) of Sutro common stock to a new employee. The grant was made as an inducement material to the employee's acceptance of employment with Sutro and was approved by the Compensation Committee of Sutro's Board of Directors in accordance with Nasdaq Listing Rule 5635(c)(4).
Neutral
GlobeNewsWire
3 months ago
Sutro Biopharma Announces Updated Data from Phase 1b Study of Luvelta in Combination with Bevacizumab at ESMO 2024
- 4.3 mg/kg of luveltamab tazevibulin (luvelta) in combination with standard dose of bevacizumab (15 mg/kg) every 3 weeks resulted in a 56% objective response rate in patients with late-stage ovarian cancer and was selected to be the recommended phase 2 dose (RP2D) -
Neutral
GlobeNewsWire
3 months ago
Sutro Biopharma to Host Research Forum Highlighting Next-Generation ADC Innovation and Near-term Pipeline, on October 10, 2024
SOUTH SAN FRANCISCO, Calif., Sept. 11, 2024 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that it will host a Research Forum to highlight its pipeline of next-generation ADCs. The live webcast will be held on Thursday, October 10, 2024, starting at 1:30 p.m. PT / 4:30 p.m. ET.
Charts implemented using Lightweight Charts™